Scintigraphic imaging of P-glycoprotein expression with a radiolabelled antibody

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 11, 2006, Pages 1266-1272

  Van Eerd, Julliëtte E M ^a   De Geus Oei, Lioe Fee ^a   Oyen, Wim J G ^a   Corstens, Frans H M ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

15D3; MDR; P glycoprotein; Radiolabelled antibody

Indexed keywords

GLYCOPROTEIN P; INDIUM 111; IODINE 131; MONOCLONAL ANTIBODY; P GLYCOPROTEIN ANTIBODY I 131; P GLYCOPROTEIN ANTIBODY PENTETIC ACID I 131; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG UPTAKE; ISOTOPE LABELING; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; RADIOACTIVITY; SCINTIGRAPHY; TUMOR CELL; UTERUS SARCOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION PROFILING; INDIUM RADIOISOTOPES; MICE; MICE, INBRED BALB C; MICE, NUDE; P-GLYCOPROTEIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; UTERINE NEOPLASMS;

EID: 33750371414     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0152-0     Document Type: Article

References (25)

1. Sharma V. Radiopharmaceuticals for assessment of multidrug resistance p-glycoprotein-mediated drug transport activity. Bioconjug Chem 2004;15:1464-1474
2. Eytan GD, Kuchel PW. Mechanism of action of P-glycoprotein in relation to passive membrane permeation. Int Rev Cytol 1999;190:175-250
3. 99mTc- labeled inhibitor of the multidrug resistant gene product P-glycoprotein. Nucl Med Biol 2000;27:135-141
4. Tatsumi M, Tsuruo T, Nishimura T. Evaluation of MS-209, a novel multidrug-resistance-reversing agent, in tumour-bearing mice by technetium-99m-MIBI imaging. Eur J Nucl Med Mol Imaging 2002;29:288-294
5. Shi T, Wrin J, Reeder J, Liu D, Ring DB. High-affinity monoclonal antibodies against P-glycoprotein. Clin Immunol Immunopathol 1995;76:44-51
6. Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999;81:741-746
7. 186Re. J Nucl Med 2004;45:327-337
8. Hnatowich DJ, Childs RL, Lanteigne D, Najafi A. The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: an improved method. J Immunol Methods 1983;65:147-157
9. 125I labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts. Cancer Biother Radiopharm 1998;13:133-139
10. Millar WT, Smith JF. Protein iodination using Iodogen. Int J Appl Radiat Isot 1983;34:639-641
11. Harker WG, Sikic BI. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res 1985;45:4091-4096
12. Harker WG, MacKintosh FR, Sikic BI. Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs. Cancer Res 1983;43:4943-4950
13. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA, Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77-89
14. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997;15:1529-1537
15. Van Oosterhout YV, van den Herik-Oudijk IE, Wessels HM, de Witte T, van de Winkel JG, Preijers FW. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins. Cancer Res 1994;54:3527-3532
16. Geus-Oei LF, Eerd-Vismale J, Molthoff C, Corstens F, Oyen W, Boerman O. Tracers to monitor the response to chemotherapy: in vitro screening of four radiopharmaceuticals. Cancer Biother Radiopharm 2004;19:457-465
17. Del Vecchio S, Ciarmiello A, Salvatore M. Scintigraphic detection of multidrug resistance in cancer. Cancer Biother Radiopharm 2000;15:327-337
18. Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996;56:2123-2129
19. Shih LB, Thorpe SR, Griffiths GL, Diril H, Ong GL, Hansen HJ, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med 1994;35:899-908
20. Hamada H, Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986;83:7785-7789
21. Meyers MB, Rittmann-Grauer L, O'Brien JP, Safa AR. Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: differential expression of the Mr 180,000 and Mr 170,000 P-glycoproteins in multidrug-resistant human tumor cells. Cancer Res 1989;49:3209-3214
22. Ballinger JR, Bannerman J, Boxen I, Firby P, Hartman NG, Moore MJ. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 1996;37:1578-1582
23. Iwahashi T, Okochi E, Ariyoshi K, Watabe H, Amann E, Mori S, et al. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model. Cancer Res 1993;53:5475-5482
24. 125I]MRK-16 monoclonal antibody. Nucl Med Biol 1995;22:497-504
25. Mechetner EB, Roninson IB. Efficient inhibition of P-glycoprotein- mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 1992;89:5824-5828